SkinBioTherapeutics plc (LON:SBTX), a life sciences company focused on skin health, announced today that it has received provisional ethics approval for its human study scheduled to start later this year.
Full approval will be granted on completion of procedural amendments to the study paperwork which are underway.
The human study, scheduled for September 2018, will be conducted on 120 female volunteers with self-assessed ‘dry skin’ over a six week period. The study is designed to test whether the positive impact of the SkinBiotix® technology on the skin’s barrier function, which has been demonstrated in laboratory studies, is replicated with human volunteers. Measurements will be taken to assess skin dryness, skin hydration and the skin barrier function.
Dr Catherine O’Neill, CEO of SkinBioTherapeutics Plc, commented: “Ethics approval is a prerequisite for human clinical trials and therefore required before our human study can commence. The procedural amendments we need to make to the paperwork are straightforward and consequently we remain on track to commence the human study in September.”